Publications by authors named "SeokYoung Choi"
High voltage spinel LiMnNiO (LMNO) is a promising energy storage material for the next generation lithium batteries with high energy densities. However, due to the major controversies in synthesis, structure, and interfacial properties of LMNO, its unsatisfactory performance is still a challenge hindering the technology's practical applications. Herein, this paper provides general characteristics of LiMnNiO such as spinel structure, electrochemical properties, and phase transition.
View Article and Find Full Text PDFArticle Synopsis
- Lazertinib is a new targeted therapy for non-small cell lung cancer (NSCLC) that has shown better efficacy than gefitinib in a study focused on Asian patients with specific EGFR mutations.
- The LASER301 phase 3 study found that patients receiving lazertinib had a significantly longer progression-free survival (20.6 months) compared to those on gefitinib (9.7 months).
- Both medications had similar safety profiles, with only slight differences in adverse events leading to discontinuation, making lazertinib a promising option for treating these patients.
Article Synopsis
- The study analyzed the effectiveness and safety of lazertinib compared to gefitinib in treating Korean patients with EGFR-mutated non-small cell lung cancer (NSCLC) as part of the phase 3 LASER301 trial.
- A total of 172 patients were randomized to receive either lazertinib (240 mg/day) or gefitinib (250 mg/day), with the main goal of assessing progression-free survival (PFS).
- Results showed that lazertinib significantly improved median PFS (20.8 months) compared to gefitinib (9.6 months) and had a similar safety profile, suggesting lazertinib could be a promising new treatment option for these patients.